Forte Biosciences Inc (FBRX) Stock Price, Quote & News

Company Profile

Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as celiac disease, vitiligo, alopecia areata, and type 1 diabetes. Forte Biosciences, Inc. is headquartered in Dallas, Texas.

Industry: Biotechnology

Sector: Healthcare

Phone: 310 618 6994

Website: www.fortebiorx.com

Address:

3060 Pegasus Park Drive, Building 6, Dallas, United States

porky1963 Aug. 3 at 7:56 PM

$FBRX just to let you know,just sold out.$76.66.DISSAPOINTED in myself but to hold out for more is greed.it's been an epic journey of up and great downs.time to move on.will study over next few weeks if we can get on early again.it was taken out of our hands.x😪

0 · Reply

porky1963 Aug. 3 at 5:31 AM

$FBRX awfull lot go'in on in pharma + biotec stocks.some very big mergers / buyouts on the table if not under the table.some old gold mines out there to reopen.look back in our portfolios just in case of shares sold.maybe its the right time to get back in.x

0 · Reply

Roronao Jul. 30 at 8:58 PM

$OTLY $FBRX 87watching

0 · Reply

porky1963 Jul. 30 at 8:15 PM

$FBRX up to asking price.

0 · Reply

porky1963 Jul. 30 at 7:55 PM

$FBRX i am wondering if this "RODEO" is over.after all the years i have been thru here i find it hard that a company that has had to fight tooth+nail to survive has finally decided to be bought out.the price is a bargain for all the hard work done over many years.i hope they keep control of future developments and have the freedom that has brought them on this journey.GREAT TEAM with a great future i hope.thanks for the ride will try and find another winner.x

0 · Reply

porky1963 Jul. 29 at 6:27 AM

$FBRX so highly likely saying good bye to my shares.so can you tell me will ARGENX pay the transaction fee and tax on my holding,if not is there any point in holding out until the takeover.they have agreed on$77 .00 a very reasonable price and i do not envisage but i may be wrong someone else turning up to the party.it seems to be moveing very fast from disclosure of the news being released.so is there any advantage to hold out for a few cents/pence.? x.

0 · Reply

SuperGreenToday Jul. 29 at 1:58 AM

$FBRX Share Price: $76.68 Contract Selected: Feb 19, 2027 $70 Calls Buy Zone: $4.33 – $5.35 Target Zone: $7.00 – $8.56 Potential Upside: 53% ROI Time to Expiration: 205 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

ExploringTrades Jul. 28 at 10:22 PM

APUS is getting a lot of attention! Could be the next massive runner! Never chase those big moves that are up 500%+ .. Easy way to lose! Key is to buy early before the runs happen! 💎 These tiny float tickers are running 100-400% recently! APUS starting to get discovered and trending on Stocktwits! Only 400k shares outstanding - keep it on watch ! MIght run like $UTZ $CJMB $FBRX Did too now!

0 · Reply

MrGreenth Jul. 28 at 8:54 PM

APUS is getting a lot of attention! Could be the next massive runner! Never chase those big moves that are up 500%+ .. Easy way to lose! Key is to buy early before the runs happen! 💎 These tiny float tickers are running 100-400% recently!! APUS starting to get discovered and trending on Stocktwits! Only 400k shares outstanding - keep it on watch bulls! MIght run like $UTZ $CJMB $FBRX Did too

0 · Reply

MX1074 Jul. 28 at 5:30 PM

$FBRX ..200$ before the end of August. Don't forget this post😉

0 · Reply

Halper Sadeh LLC is Investigating Whether FBRX and SAFT are Obtaining Fair Deals for their Shareholders

SAFT

2026-07-28T08:45:21.000Z - 13 days ago

Forte Biosciences downgraded to Equal Weight from Overweight at Barclays

2026-07-27T16:05:35.000Z - 14 days ago

After Forte acquisition, H.C. Wainwright says First Tracks could be target

ARGX TRAX

2026-07-27T15:40:08.000Z - 14 days ago

Forte Biosciences downgraded to Hold from Buy at Brookline

2026-07-27T15:05:28.000Z - 14 days ago

Forte Biosciences downgraded to In Line from Outperform at Evercore ISI

ARGX

2026-07-27T12:20:40.000Z - 14 days ago

Forte Biosciences downgraded to Hold from Buy at TD Cowen

2026-07-27T12:20:14.000Z - 14 days ago

M&A News: Forte Biosciences Shares Leap 40% After Argenx Seals $2.2B Immunology Deal

ARGX

2026-07-27T09:20:07.000Z - 14 days ago

Argenx to acquire Forte Biosciences for $77 per share in cash

ARGX

Jul 27, 2026, 1:29 AM EDT - 15 days ago

Argenx to Buy Forte Biosciences for $2.2 Billion

ARGX

Jul 27, 2026, 1:15 AM EDT - 15 days ago

Argenx to buy Forte Biosciences for about $2.2 billion

ARGX

Jul 27, 2026, 1:07 AM EDT - 15 days ago

argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class Anti-CD122 Antibody, FB102, to Its Immunology Pipeline

ARGX

2026-07-21T08:50:08.000Z - 20 days ago

Forte Biosciences initiated with an Overweight at Barclays

2026-07-10T16:14:01.000Z - 4 weeks ago

Why Is Forte Biosciences (FBRX) Stock Up Today?

2026-07-09T13:45:17.000Z - 4 weeks ago

Forte Biosciences trading resumes

2026-07-09T13:35:25.000Z - 4 weeks ago

Forte Biosciences trading halted, volatility trading pause

Jul 9, 2026, 8:30 AM EDT - 4 weeks ago

Forte Biosciences Transcript: Study result

Jul 9, 2026, 8:30 AM EDT - 4 weeks ago

Forte Biosciences Slides: Study result

Jul 9, 2026, 8:30 AM EDT - 4 weeks ago

Forte Biosciences Press release: Study result

2026-07-09T12:11:15.000Z - 4 weeks ago

Forte Biosciences’ FB102 shows efficacy in vitiligo Phase 1b study

Jul 9, 2026, 8:00 AM EDT - 4 weeks ago

FB102 Achieves Statistically Significant Improvement in Vitiligo at Week 24 After Completion of 12-Week Treatment Period

Jun 8, 2026, 8:00 AM EDT - 2 months ago

Forte Biosciences Registration statement: Registration filing

Jun 2, 2026, 8:00 AM EDT - 2 months ago

Forte Biosciences Registration statement: Registration filing

May 11, 2026, 4:01 PM EDT - 3 months ago

Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules

May 11, 2026, 9:01 AM EDT - 3 months ago

Forte Biosciences, Inc. Announces First Quarter 2026 Results and Provides Update

May 11, 2026, 7:00 AM EDT - 3 months ago

Forte Biosciences Quarterly report: Q1 2026

May 11, 2026, 7:00 AM EDT - 3 months ago

Forte Biosciences Earnings release: Q1 2026

Apr 29, 2026, 8:00 AM EDT - 3 months ago

Forte Biosciences Proxy statement: Proxy filing

Apr 8, 2026, 9:30 PM EDT - 4 months ago

Forte Biosciences Announces Pricing of $150 Million Public Offering

Apr 8, 2026, 4:02 PM EDT - 4 months ago

Forte Biosciences Announces Proposed Public Offering

Mar 31, 2026, 4:01 PM EDT - 4 months ago

Forte Biosciences, Inc. Announces 2025 Results and Provides Update

Mar 31, 2026, 7:00 AM EDT - 4 months ago

Forte Biosciences Earnings release: Q4 2025

Mar 31, 2026, 7:00 AM EDT - 4 months ago

Forte Biosciences Annual report: Q4 2025

Mar 17, 2026, 4:01 PM EDT - 5 months ago

Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules

Mar 4, 2026, 4:01 PM EST - 5 months ago

Forte Biosciences, Inc. Reports Inducement Grants Under NASDAQ Listing Rules

Feb 9, 2026, 4:01 PM EST - 6 months ago

Forte Biosciences, Inc. to Present at Upcoming Investor Meetings

Nov 14, 2025, 9:00 AM EST - 9 months ago

Forte Biosciences, Inc. Announces Third Quarter 2025 Results and Provides Update

Nov 14, 2025, 7:00 AM EST - 9 months ago

Forte Biosciences Earnings release: Q3 2025

Nov 14, 2025, 7:00 AM EST - 9 months ago

Forte Biosciences Quarterly report: Q3 2025

Nov 13, 2025, 7:00 AM EST - 9 months ago

Forte Biosciences Slides: Corporate presentation

Nov 3, 2025, 4:01 PM EST - 10 months ago

Forte Biosciences, Inc. to Present at Upcoming Healthcare Conferences

Sep 15, 2025, 9:00 AM EDT - 11 months ago

Forte Biosciences, Inc. Announces Presentation of FB102 Celiac Disease Trial at Tampere Celiac Disease Symposium

Aug 14, 2025, 4:01 PM EDT - 1 year ago

Forte Biosciences, Inc. Announces Results and Provides Update

Aug 14, 2025, 4:00 PM EDT - 1 year ago

Forte Biosciences Earnings release: Q2 2025

Aug 14, 2025, 4:00 PM EDT - 1 year ago

Forte Biosciences Quarterly report: Q2 2025

Jun 25, 2025, 12:28 AM EDT - 1 year ago

Forte Biosciences Announces Pricing of $75 Million Public Offering

Jun 23, 2025, 8:30 AM EDT - 1 year ago

Forte Biosciences Transcript: Study Update

Jun 23, 2025, 8:30 AM EDT - 1 year ago

Forte Biosciences Press release: Study Update

Jun 23, 2025, 8:30 AM EDT - 1 year ago

Forte Biosciences Slides: Study Update

Jun 23, 2025, 7:18 AM EDT - 1 year ago

Forte Biosciences Announces Positive Data in FB102 Celiac Disease Phase 1B Study

May 15, 2025, 4:00 PM EDT - 1 year ago

Forte Biosciences Earnings release: Q1 2025

May 15, 2025, 4:00 PM EDT - 1 year ago

Forte Biosciences Quarterly report: Q1 2025

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Forte Biosciences Proxy statement: Proxy Filing

Mar 31, 2025, 9:00 AM EDT - 1 year ago

Forte Biosciences, Inc. Announces Results and Provides Clinical Update

Mar 30, 2025, 6:00 PM EDT - 1 year ago

Forte Biosciences Earnings release: Q4 2024

Mar 30, 2025, 6:00 PM EDT - 1 year ago

Forte Biosciences Annual report: Q4 2024

Mar 28, 2025, 8:00 AM EDT - 1 year ago

Forte Biosciences Registration statement: Registration Filing

Dec 31, 2024, 7:00 AM EST - 1 year ago

Forte Biosciences Proxy statement: Proxy Filing

Dec 13, 2024, 7:00 AM EST - 1 year ago

Forte Biosciences Registration statement: Registration Filing

Nov 25, 2024, 9:00 AM EST - 1 year ago

Forte Biosciences to Host R&D Day December 3, 2024

Nov 20, 2024, 9:00 AM EST - 1 year ago

Forte Biosciences, Inc. Announces Oversubscribed $53 Million Private Placement From Leading Healthcare Institutional Investors to Advance FB102 Across Autoimmune Indications

Nov 14, 2024, 4:01 PM EST - 1 year ago

Forte Biosciences, Inc. Announces Third Quarter 2024 Results and Provides Business Update

Nov 14, 2024, 4:00 PM EST - 1 year ago

Forte Biosciences Quarterly report: Q3 2024

Aug 14, 2024, 4:01 PM EDT - 2 years ago

Forte Biosciences, Inc. Announces Second Quarter 2024 Results and Provides Business Update

Aug 14, 2024, 12:01 PM EDT - 2 years ago

Forte Biosciences Quarterly report: Q2 2024

Aug 14, 2024, 12:01 PM EDT - 2 years ago

Forte Biosciences Earnings release: Q2 2024

Jul 30, 2024, 8:00 AM EDT - 2 years ago

Forte Biosciences Proxy statement: Proxy Filing

Jul 19, 2024, 8:00 AM EDT - 2 years ago

Forte Biosciences Proxy statement: Proxy Filing

May 13, 2024, 4:05 PM EDT - 2 years ago

Forte Biosciences, Inc. Announces First Quarter 2024 Results and Provides Business Update

May 13, 2024, 7:00 AM EDT - 2 years ago

Forte Biosciences Quarterly report: Q1 2024

May 13, 2024, 7:00 AM EDT - 2 years ago

Forte Biosciences Earnings release: Q1 2024

Mar 18, 2024, 4:05 PM EDT - 2 years ago

Forte Biosciences, Inc. Announces 2023 Results and Provides Business Update

Mar 18, 2024, 8:00 AM EDT - 2 years ago

Forte Biosciences Earnings release: Q4 2023

Mar 18, 2024, 8:00 AM EDT - 2 years ago

Forte Biosciences Annual report: Q4 2023

Nov 13, 2023, 4:01 PM EST - 2 years ago

Forte Biosciences, Inc. Announces Third Quarter 2023 Results and Provides Business Update

Nov 13, 2023, 4:00 PM EST - 2 years ago

Forte Biosciences Quarterly report: Q3 2023

Sep 14, 2023, 10:50 AM EDT - 3 years ago

ISS and Glass Lewis Recommend Forte Biosciences Stockholders Vote FOR Boardroom Change at the Company's Upcoming Annual Meeting

Sep 6, 2023, 3:15 PM EDT - 3 years ago

Concerned Stockholders of Forte Biosciences and Its Independent Director Candidates Share Key Facts that Reinforce the Need for Urgent Change in the Company's Boardroom

Sep 1, 2023, 8:00 AM EDT - 3 years ago

Forte Biosciences Proxy statement: Proxy Filing

Aug 31, 2023, 8:00 AM EDT - 3 years ago

Forte Biosciences Proxy statement: Proxy Filing

Aug 29, 2023, 8:00 AM EDT - 3 years ago

Forte Biosciences Registration statement: Registration Filing

Aug 25, 2023, 8:00 AM EDT - 3 years ago

Concerned Stockholders of Forte Biosciences File Definitive Proxy Statement and Send Letter to Stockholders

Aug 24, 2023, 8:00 AM EDT - 3 years ago

Forte Biosciences Proxy statement: Proxy Filing

Aug 24, 2023, 8:00 AM EDT - 3 years ago

Forte Biosciences Proxy statement: Proxy Filing

Aug 14, 2023, 4:01 PM EDT - 3 years ago

Forte Biosciences, Inc. Announces Second Quarter 2023 Results and Provides Business Update

Aug 14, 2023, 7:00 AM EDT - 3 years ago

Forte Biosciences Quarterly report: Q2 2023

Aug 2, 2023, 8:00 AM EDT - 3 years ago

Forte Biosciences Proxy statement: Proxy Filing

Aug 1, 2023, 4:01 PM EDT - 3 years ago

Forte Biosciences, Inc. Announces $25 Million Financing and R&D Update for FB-102

May 25, 2023, 8:00 AM EDT - 3 years ago

Forte Biosciences Proxy statement: Proxy Filing

May 15, 2023, 4:01 PM EDT - 3 years ago

Forte Biosciences, Inc. Announces First Quarter 2023 Results and Provides Business Update

Mar 31, 2023, 4:05 PM EDT - 3 years ago

Forte Biosciences, Inc. Announces Full Year 2022 Results and Provides Business Update

Mar 31, 2023, 8:00 AM EDT - 3 years ago

Forte Biosciences Annual report: Q4 2022

Jan 12, 2023, 4:05 PM EST - 3 years ago

Mr. David Gryska Appointed to Forte Biosciences Board of Directors

Nov 14, 2022, 4:01 PM EST - 4 years ago

Dr. Scott Brun, M.D. Appointed to Forte Biosciences Board of Directors

Nov 14, 2022, 4:01 PM EST - 4 years ago

Forte Biosciences, Inc. Announces Third Quarter 2022 Results and Provides Business Update

Aug 17, 2022, 8:00 AM EDT - 4 years ago

Camac Partners Condemns Forte Biosciences' Seemingly Defensive and Unjustifiable Capital Raise

Aug 15, 2022, 4:05 PM EDT - 4 years ago

Forte Biosciences, Inc. Announces Second Quarter 2022 Results and Provides Business Update

Jun 7, 2022, 9:00 AM EDT - 4 years ago

Forte Biosciences, Inc. Announces the Appointment of Dr. Hubert Chen, MD as Chief Scientific Officer and President

May 19, 2022, 8:00 AM EDT - 4 years ago

Forte Biosciences Proxy statement: Proxy Filing

May 16, 2022, 9:00 AM EDT - 4 years ago

Forte Biosciences, Inc. Announces First Quarter 2022 Results and Provides Business Update

Apr 29, 2022, 8:00 AM EDT - 4 years ago

Forte Biosciences Proxy statement: Proxy Filing

Mar 31, 2022, 8:00 AM EDT - 4 years ago

Forte Biosciences Annual report: Q4 2021

Sep 3, 2021, 12:19 PM EDT - 5 years ago

A small biotech firm just plummeted 82% after abandoning a drug candidate due to failed phase 2 trial

Sep 3, 2021, 7:21 AM EDT - 5 years ago

Forte Biosciences stock plunges more than 80% after 'disappointing' trial results of atopic dermatitis treatment

Sep 2, 2021, 4:05 PM EDT - 5 years ago

Clinical Trial of FB-401 For the Treatment of Atopic Dermatitis Fails to Meet Statistical Significance

porky1963 Aug. 3 at 7:56 PM

0 · Reply

porky1963 Aug. 3 at 5:31 AM

0 · Reply

Roronao Jul. 30 at 8:58 PM

$OTLY $FBRX 87watching

0 · Reply

porky1963 Jul. 30 at 8:15 PM

$FBRX up to asking price.

0 · Reply

porky1963 Jul. 30 at 7:55 PM

0 · Reply

porky1963 Jul. 29 at 6:27 AM

0 · Reply

SuperGreenToday Jul. 29 at 1:58 AM

0 · Reply

ExploringTrades Jul. 28 at 10:22 PM

0 · Reply

MrGreenth Jul. 28 at 8:54 PM

APUS is getting a lot of attention! Could be the next massive runner! Never chase those big moves that are up 500%+ .. Easy way to lose! Key is to buy early before the runs happen! 💎 These tiny float tickers are running 100-400% recently!! APUS starting to get discovered and trending on Stocktwits! Only 400k shares outstanding - keep it on watch bulls! MIght run like $UTZ $CJMB $FBRX Did too

0 · Reply

MX1074 Jul. 28 at 5:30 PM

$FBRX ..200$ before the end of August. Don't forget this post😉

0 · Reply

tradehulk Jul. 28 at 4:57 PM

$FBRX $FIG $FRMI 🚨 $CHAI volume up 1300% on expanded TikTok Partnership 🚀

0 · Reply

topstockalerts Jul. 28 at 2:28 PM

$FBRX 👀

0 · Reply

Powell6531 Jul. 28 at 2:10 PM

$FBRX $GOSS $KIDZ $MTNB $NCTY

0 · Reply

topstockalerts Jul. 28 at 2:05 PM

Top Gainers PT2 $GOSS $KIDZ $NCTY $FBRX $MTNB

0 · Reply

prismmarketview Jul. 28 at 1:11 PM

🚨 DEAL ALERT: argenx $ARGX is acquiring Forte Biosciences $FBRX for ~$2.2B — $77/share cash, an 86% premium. $FBRX popped ~39% premarket. The prize? FB102, Forte's autoimmune candidate for vitiligo & celiac disease. Read more 👇 #biotech #pharma #MergersAndAcquisitions https://prismmarketview.com/argenx-swoops-on-forte-biosciences-in-2-2-billion-immunology-bet/

0 · Reply

Market_Pulse_Report Jul. 28 at 12:13 PM

$FBRX

0 · Reply

Tumbleweedloseshismoney Jul. 28 at 3:28 AM

$FBRX dang, glad i obeyed my stop

0 · Reply

topstockalerts Jul. 28 at 2:15 AM

$FBRX it’s funny how the quiet ones can become the strongest.

0 · Reply

masonjoel99 Jul. 28 at 2:03 AM

$AAPL $FBRX $NVDA $RTX probably earnings leak…insiders buying…maybe Nancy pelosi….

0 · Reply

ShKumaresan Jul. 28 at 1:59 AM

$AAPL $NVDA $RTX $FBRX Why Did AAPL, FBRX, RTX Stocks Surge To 52-Week Highs Today? https://stocktwits.com/news-articles/default/equity/why-did-aapl-fbrx-rtx-stocks-surge-to-52-week-highs-today/cZZC4XQR76C

2 · Reply

StocktwitsNews Jul. 28 at 1:57 AM

Why Did AAPL, FBRX, RTX Stocks Surge To 52-Week Highs Today? $AAPL $FBRX $RTX $NVDA https://stocktwits.com/news/equity/markets/why-did-aapl-fbrx-rtx-stocks-surge-to-52-week-highs-today/cZZC4XQR76C

0 · Reply

Market Cap	1.07B
Revenue (ttm)	0.00
Net Income (ttm)	-69.38M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	765,200
Avg Vol	1,266,846
Day's Range	N/A - N/A
Shares Out	13.89M
Stochastic %K	46%
Beta	2.62
Analysts	Sell
Price Target	$76.60